Adams Respiratory starts phase 2 trial of erdosteine for chronic bronchitis

By Elaine Rigoli

Tampa, Fla., March 30 - Adams Respiratory Therapeutics, Inc. has started its phase 2 clinical trial of erdosteine, a mucoregulator and antioxidant drug that the company in-licensed from Edmond Pharma, SRL for U.S. development.

Adams filed its Investigational New Drug application for erdosteine in January, according to a news release.

The placebo-controlled investigational study will evaluate different dose levels and clinical methods in roughly 400 patients with chronic bronchitis associated with chronic obstructive pulmonary disorder, the company said.

Erdosteine is marketed in more than 30 countries outside of the United States for the treatment of acute and chronic bronchitis and has more than 24 million patient exposures.

Adams is a specialty pharmaceutical company based in Chester, N.J., that develops, commercializes and markets over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.

Edmond Pharma develops chemicals and pharmaceuticals. The company is located in Paderno Dugnano, north of Milan, Italy.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.